Skip to main content
OpenTrials
Completed

NCT Number: NCT01792427

Mortality in Non-cystic Fibrosis Bronchiectasis

In this study we analyzed the overall survival for all newly diagnosed patients with non-cystic fibrosis bronchiectasis from June 2006 onwards. The investigators wanted to confirm the known risk factors such as age, gender, smoking history and Pseudomonas aeruginosa and evaluate the impact on survival of etiology, number of different bacteriological species in retrospective and prospective sputa, azithromycin use and presence/development of pulmonary hypertension.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Non-cystic Fibrosis Bronchiectasis

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

UZ Leuven

Leuven, Vlaams-Brabant, 3000, Belgium

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients with clinically significant and radiologically proven bronchiectasis
  • Chest CT scan confirming the presence of bronchiectatic lesions and had symptoms of chronic productive cough
  • Bronchiectasis was deemed to be present if there was one or more of the following criteria: a bronchoarterial ratio greater than 1, lack of tapering of the bronchi and visualization of bronchi within 1 cm of costal or paravertebral pleura or abutting the mediastinal pleura

Exclusion criteria

  • diagnosis of cystic fibrosis
  • underlying tumoral problem causing the bronchiectatic lesions (postradiotherapy, secondary immunodeficiency due to chemotherapy or postinfectious due to tumoral obstruction)
  • patients with asymptomatic traction bronchiectasis caused by interstitial lung disease

Treatment and study plan

Primary outcomes

  1. overall survival

    Time frame: 6 years 4 months

Secondary outcomes

  1. risk factor identification for NCFB

    Time frame: 6 years 4 months

    The investigators wanted to confirm the known risk factors such as age, gender, smoking history and Pseudomonas aeruginosa.

Other outcomes

  1. Identify cause of death

    Time frame: 6 years 4 months

    If death occurred, the patient file was reassessed to identify cause of death.

  2. risk factor identification for the survival of NCFB

    Time frame: 6 years 4 months

    The investigators will evaluate the impact of etiology, number of different bacteriological species in retrospective and prospective sputa, azithromycin use and presence/development of pulmonary hypertension on survival .

Sponsors and collaborators

Lead sponsor

Universitaire Ziekenhuizen KU Leuven

Other

Registry information

Official study title

Mortality in Non-cystic Fibrosis Bronchiectasis: a Long-term Cohort Analysis

Important dates

Study start
2006
Primary completion
2012
Study completion
2012
First posted
Feb 15, 2013
Registry last updated
Feb 20, 2013

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.